15 February 2017

NICE, Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT

Final agenda

The meeting will start promptly at 09:30 and is expected to finish at approximately 17:30.

Please note that this agenda is subject to change prior to the meeting.

  1. Welcome and introduction to format of meeting – Part 1 only (open session)
  2. Apologies – Part 1 only (open session)
  3. Any other business – Part 1 only (open session)
  4. Minutes from the last Committee meeting held on Wednesday 18 January 2017 – Part 1 only (open session)
  5. Appraisal of adalimumab and dexamethasone for treating non-infectious uveitis [ID763]
    • 5.1. Declarations of interest – Part 1 only (open session)
    • 5.2. Introduction by Vice Chair, Professor Eugene Milne – Part 1 only (open session)
    • 5.3. Presentation by the lead team, Gail Coster, Professor Andrea Manca and Judith Wardle – Part 1 AND part 2 (open and closed session)
    • 56.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) – Part 2 only (closed session)
  6. Appraisal of carfilzomib for treated multiple myeloma [ID934]
    • 6.1. Declarations of interest – Part 1 only (open session)
    • 6.2. Introduction by the Vice Chair, Professor Eugene Milne – Part 1 only (open session)
    • 6.3. Presentation by the Vice Chair, Professor Eugene Milne – Part 1 AND part 2 (open and closed session)
    • 6.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) – Part 2 only (closed session)
  7. Appraisal of nivolumab for treating relapsed or refractory classical Hodgkin lymphoma [ID972]
    • 7.1. Declarations of interest – Part 1 only (open session)
    • 7.2. Introduction by the Chair, Professor Andrew Stevens – Part 1 only (open session)
    • 7.3. Presentation by the lead team, Dr Nigel Langford, Professor Stephen O'Brien and Judith Wardle – Part 1 AND part 2 (open and closed session)
    • 7.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) – Part 2 only (closed session)
  8. Appraisal of brentuximab vedotin for treating CD30-positive Hodgkin's lymphoma [ID722]
    • 8.1. Declarations of interest – Part 1 only (open session)
    • 8.2. Introduction by the Chair, Professor Andrew Stevens – Part 1 only (open session)
    • 8.3. Presentation by the Chair, Professor Andrew Stevens – Part 1 AND part 2 (open and closed session)
    • 8.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) – Part 2 only (closed session)

To print an agenda, please right click and select 'Print' from the menu.

Date, time and venue of next meeting

The next meeting will take place on Thursday 16 March 2017 at NICE, Level 1A, City Tower, Piccadilly Plaza, Manchester, M1 4BT.

Please note all timings are approximate.

How to register

  • Click on the register link below and complete the registration form, selecting the topics you would like to attend.
  • You will receive an automated email response when you submit the registration form. If you do not receive this automated response your registration request has not been received, and you will need to complete and submit the registration form again.
  • Registration will close on Wednesday 1 February 2017Please note that it may not be possible to accept late requests. 
  • Should you have queries regarding attending this meeting, please contact the Meetings in Public Coordinator Sandra Robinson.
  • Registrants wishing to conduct a research study on committee meetings and/or NICE processes will require prior permission. Contact the NICE Enquiry Handling team at nice@nice.org.uk.
  • Further information about conducting research is also available in our common questions and answers about meetings in public document.

 

Registration period: 18 January 2017 to 01 February 2017
Registration is closed.